Prihlásiť sa Zaregistrujte sa zadarmo

Trhová kapitalizácia spoločnosti Cellectis

Aká je hodnota metriky Trhová kapitalizácia spoločnosti Cellectis?

Hodnota metriky Trhová kapitalizácia spoločnosti Cellectis je $96.40M

Aká je definícia metriky Trhová kapitalizácia?



Trhová kapitalizácia (Market cap) je trhová hodnota vydaných akcií obchodovanej spoločnosti a je rovná cene akcie v danom čase vynásobenej počtom kusov vydaných akcií.

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Trhová kapitalizácia spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Cellectis

Čomu sa venuje spoločnosť Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Firmy s metrikou trhová kapitalizácia podobnou spoločnosti Cellectis